Gene-expression profiling in pancreatic cancer

Expert Review of Molecular Diagnostics

Volumn 10, Issue 5, 2010, Pages 591-601

  López Casas, Pedro P ^a   López Fernández, Luís A ^b  

^a Centro Nacional de Investigations Oncológicas   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

gene expression; microarray; miRs; pancreatic cancer

Indexed keywords

ACTIN; ALPHA AMYLASE PANCREAS ISOENZYME; CALDESMON; CELLULAR RETINOL BINDING PROTEIN 1; CYTOCHROME B5; ERLOTINIB; FASCIN; GEMCITABINE; KERATIN; MICRORNA; PROTEIN; PROTEIN PRECURSOR; PROTEIN S 100; PROTEIN S100P; SERINE PROTEINASE; TRIPARTITE MOTIF CONTAINING PROTEIN 29; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER SURVIVAL; CYSTADENOCARCINOMA; DOWN REGULATION; EARLY DIAGNOSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HUMAN; MICROARRAY ANALYSIS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS INTRAEPITHELIAL NEOPLASIA; PANCREAS ISLET CELL CARCINOMA; PROGNOSIS; REVIEW; UPREGULATION; GENETIC DATABASE; GENETICS; MEDLINE; METABOLISM; MORTALITY; PANCREATIC NEOPLASMS; PATHOLOGY; PUBLICATION;

DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROARRAY ANALYSIS; MICRORNAS; PANCREATIC NEOPLASMS; PERIODICALS AS TOPIC; PUBMED; TUMOR MARKERS, BIOLOGICAL;

EID: 77954748577     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.10.43     Document Type: Review

References (84)

1. Li C, Heidt DG, Dalerba P et al. Identification of pancreatic cancer stem cells. Cancer Res. 67(3), 1030-1037 (2007).
2. Maitra A, Hruban RH. Pancreatic cancer. Annu. Rev. Pathol. 3, 157-188 (2008).
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J. Clin. 59(4), 225-249 (2009).
4. Lau MK, Davila JA, Shaib YH. Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas 39(4), 458-462 (2010).
5. Mueller MT, Hermann PC, Heeschen C. Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. Front Biosci. 2, 602-613 (2010).
6. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20(10), 1218-1249 (2006).
7. Buchholz M, Gress TM. Molecular changes in pancreatic cancer. Expert Rev. Anticancer Ther. 9(10), 1487-1497 (2009).
8. Kern SE, Hruban RH, Hidalgo M, Yeo CJ. An introduction to pancreatic adenocarcinoma genetics, pathology and therapy. Cancer Biol. Ther. 1(6), 607-613 (2002).
9. Hruban RH, Bishop Pitman M, Klimstra DS. Atlas of Tumor Pathology: Tumors of the Pancreas. Fourth Series Sobin LH, Albores-Saavedra J (Eds). ARP Press, Washington, DC, USA (2006).
10. Kwei KA, Bashyam MD, Kao J et al. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet. 4(5), e1000081 (2008).
11. Kimmelman AC, Hezel AF, Aguirre AJ et al. Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc. Natl Acad. Sci. USA 105(49), 19372-19377 (2008).
12. Jones S, Zhang X, Parsons DW et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321(5897), 1801-1806 (2008).
13. Eckel F, Schneider G, Schmid RM. Pancreatic cancer: a review of recent advances. Expert Opin. Investig. Drugs 15(11), 1395-1410 (2006).
14. Crnogorac-Jurcevic T, Efthimiou E, Capelli P et al. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 20(50), 7437-7446 (2001).
15. Shi L, Reid LH, Jones WD et al. The MicroArray Quality Control (MAQC) project shows inter-and intraplatform reproducibility of gene expression measurements. Nat. Biotechnol. 24(9), 1151-1161 (2006).
16. Brazma A, Hingamp P, Quackenbush J et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat. Genet. 29(4), 365-371 (2001).
17. Edgar R, Barrett T. NCBI GEO standards and services for microarray data. Nat. Biotechnol. 24(12), 1471-1472 (2006).
18. Barrett T, Troup DB, Wilhite SE et al. NCBI GEO: mining tens of millions of expression profiles -database and tools update. Nucleic Acids Res. 35(Database issue), D760-D765 (2007).
19. Parkinson H, Kapushesky M, Kolesnikov N et al. ArrayExpress update -from an archive of functional genomics experiments to the atlas of gene expression. Nucleic Acids Res. 37(Database issue), D868-D872 (2009).
20. Rhodes DR, Kalyana-Sundaram S, Mahavisno V et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9(2), 166-180 (2007).
21. Chelala C, Hahn SA, Whiteman HJ et al. Pancreatic expression database: a generic model for the organization, integration and mining of complex cancer datasets. BMC Genomics 8, 439 (2007).
22. Vilardell F, Iacobuzio-Donahue CA. Cancer gene profiling in pancreatic cancer. Methods Mol. Biol. 576, 279-292 (2010).
23. Argani P, Iacobuzio-Donahue C, Ryu B et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin. Cancer Res. 7(12), 3862-3868 (2001).
24. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res. 62(10), 2890-2896 (2002).
25. Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol. Cancer Ther. 6(4), 1186-1197 (2007).
26. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T et al. Expression profiling of microdissected pancreatic adenocarcinomas. Oncogene 21(29), 4587-4594 (2002).
27. Logsdon CD, Simeone DM, Binkley C et al. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 63(10), 2649-2657 (2003).
28. Grutzmann R, Pilarsky C, Ammerpohl O et al. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia 6(5), 611-622 (2004).
29. Buchholz M, Braun M, Heidenblut A et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 24(44), 6626-6636 (2005).
30. Grutzmann R, Boriss H, Ammerpohl O et al. Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 24(32), 5079-5088 (2005).
31. Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology 55(88), 2016-2027 (2008).
32. Pilarsky C, Ammerpohl O, Sipos B et al. Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J. Cell. Mol. Med. 12(6B), 2823-2835 (2008).
33. Chelala C, Lemoine NR, Hahn SA, Crnogorac-Jurcevic T. A web-based platform for mining pancreatic expression datasets. Pancreatology 9(4), 340-343 (2009).
34. Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 7(9), R80 (2006).
35. Anderson NL, Polanski M, Pieper R et al. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell Proteomics 3(4), 311-326 (2004).
36. Crnogorac-Jurcevic T, Gangeswaran R, Bhakta V et al. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 129(5), 1454-1463 (2005).
37. Crnogorac-Jurcevic T, Missiaglia E, Blaveri E et al. Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J. Pathol. 201(1), 63-74 (2003).
38. Friess H, Ding J, Kleeff J et al. Microarray-based identification of differentially expressed growth-and metastasis-associated genes in pancreatic cancer. Cell. Mol. Life Sci. 60(6), 1180-1199 (2003).
39. Hu L, Evers S, Lu ZH, Shen Y, Chen J. Two-dimensional protein database of human pancreas. Electrophoresis 25(3), 512-518 (2004).
40. Iacobuzio-Donahue CA, Maitra A, Shen-Ong GL et al. Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am. J. Pathol. 160(4), 1239-1249 (2002).
41. Lu Z, Hu L, Evers S, Chen J, Shen Y. Differential expression profiling of human pancreatic adenocarcinoma and healthy pancreatic tissue. Proteomics 4(12), 3975-3988 (2004).
42. Maitra A, Hansel DE, Argani P et al. Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin. Cancer Res. 9(16 Pt 1), 5988-5995 (2003).
43. Nakamura T, Furukawa Y, Nakagawa H et al. Genome-wide cDNA microarray analysis of gene expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene 23(13), 2385-2400 (2004).
44. Shen J, Person MD, Zhu J, Abbruzzese JL, Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 64(24), 9018-9026 (2004).
45. Tan ZJ, Hu XG, Cao GS, Tang Y. Analysis of gene expression profile of pancreatic carcinoma using cDNA microarray. World J. Gastroenterol. 9(4), 818-823 (2003). (Pubitemid 36531568)
46. Terris B, Blaveri E, Crnogorac-Jurcevic T et al. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am. J. Pathol. 160(5), 1745-1754 (2002).
47. Van Heek NT, Maitra A, Koopmann J et al. Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol. Ther. 3(7), 651-656 (2004).
48. Segara D, Biankin AV, Kench JG et al. Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin. Cancer Res. 11(9), 3587-3596 (2005).
49. Iacobuzio-Donahue CA, Maitra A, Olsen M et al. Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am. J. Pathol. 162(4), 1151-1162 (2003).
50. Ishikawa M, Yoshida K, Yamashita Y et al. Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells. Cancer Sci. 96(7), 387-393 (2005).
51. Nakata K, Nagai E, Ohuchida K et al. S100P is a novel marker to identify intraductal papillary mucinous neoplasms. Hum. Pathol. 41(6), 824-831 (2010).
52. Harsha HC, Kandasamy K, Ranganathan P et al. A compendium of potential biomarkers of pancreatic cancer. PLoS Med. 6(4), e1000046 (2009).
53. Yeo CJ, Cameron JL, Lillemoe KD et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann. Surg. 221(6), 721-731 (1995).
54. Brugge WR, Lauwers GY, Sahani D, Fernandez-del Castillo C, Warshaw AL. Cystic neoplasms of the pancreas. N. Engl. J. Med. 351(12), 1218-1226 (2004).
55. Maitra A, Fukushima N, Takaori K, Hruban RH. Precursors to invasive pancreatic cancer. Adv. Anat. Pathol. 12(2), 81-91 (2005).
56. Deng H, Shi J, Wilkerson M, Meschter S, Dupree W, Lin F. Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens. Am. J. Clin. Pathol. 129(1), 81-88 (2008).
57. Suomela S, Cao L, Bowcock A, Saarialho-Kere U. Interferon a-inducible protein 27 (IFI27) is upregulated in psoriatic skin and certain epithelial cancers. J. Invest. Dermatol. 122(3), 717-721 (2004).
58. Chen R, Brentnall TA, Pan S et al. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol. Cell Proteomics 6(8), 1331-1342 (2007).
59. Orchekowski R, Hamelinck D, Li L et al. Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res. 65(23), 11193-11202 (2005).
60. Ingvarsson J, Wingren C, Carlsson A et al. Detection of pancreatic cancer using antibody microarray-based serum protein profiling. Proteomics 8(11), 2211-2219 (2008). (Pubitemid 351898027)
61. Shi WD, Meng ZQ, Chen Z, Lin JH, Zhou ZH, Liu LM. Identification of liver metastasis-related genes in a novel human pancreatic carcinoma cell model by microarray analysis. Cancer Lett. 283(1), 84-91 (2009).
62. Campagna D, Cope L, Lakkur SS, Henderson C, Laheru D, Iacobuzio-Donahue CA. Gene expression profiles associated with advanced pancreatic cancer. Int. J. Clin. Exp. Pathol. 1(1), 32-43 (2008).
63. Nakahira S, Nakamori S, Tsujie M et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. Int. J. Cancer 120(6), 1355-1363 (2007).
64. Ina S, Hirono S, Noda T, Yamaue H. Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: increased expression of interferon-stimulated gene 15 kd is associated with intrinsic chemoresistance. Pancreas 39(4), 473-485 (2010).
65. Bai J, Sata N, Nagai H. Gene expression analysis for predicting gemcitabine sensitivity in pancreatic cancer patients. HPB (Oxford) 9(2), 150-155 (2007).
66. Messersmith WA, Rajeshkumar NV, Tan AC et al. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol. Cancer Ther. 8(6), 1484-1493 (2009).
67. Li S, Couet J, Lisanti MP. Src tyrosine kinases, Ga subunits, and H-Ras share a common membrane-anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J. Biol. Chem. 271(46), 29182-29190 (1996).
68. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75(5), 843-854 (1993).
69. Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A, Yakhini Z. Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS ONE 4(11), e8003 (2009).
70. Wang L, Tang H, Thayanithy V et al. Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res. 69(24), 9490-9497 (2009).
71. Cheng C, Fu X, Alves P, Gerstein M. mRNA expression profiles show differential regulatory effects of microRNAs between estrogen receptor-positive and estrogen receptor-negative breast cancer. Genome Biol. 10(9), R90 (2009).
72. Arndt GM, Dossey L, Cullen LM et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 9, 374 (2009).
73. Bloomston M, Frankel WL, Petrocca F et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297(17), 1901-1908 (2007).
74. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg. 12(12), 2171-2176 (2008).
75. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int. J. Cancer 126(1), 73-80 (2010).
76. Lee EJ, Gusev Y, Jiang J et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 120(5), 1046-1054 (2007). (Pubitemid 46214304)
77. Zhang Y, Li M, Wang H et al. Profiling of 95 microRNAs in pancreatic cancer cell lines and surgical specimens by real-time PCR analysis. World J. Surg. 33(4), 698-709 (2009).
78. Szafranska AE, Davison TS, John J et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26(30), 4442-4452 (2007).
79. Cardinali B, Castellani L, Fasanaro P et al. MicroRNA-221 and microRNA-222 modulate differentiation and maturation of skeletal muscle cells. PLoS ONE 4(10), e7607 (2009).
80. Li Y, VandenBoom TG 2nd, Kong D et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 69(16), 6704-6712 (2009).
81. Park JK, Lee EJ, Esau C, Schmittgen TD. Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 38(7), e190-e199 (2009).
82. Wang J, Chen J, Chang P et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev. Res. 2(9), 807-813 (2009).
83. Capurso G, Lattimore S, Crnogorac-Jurcevic T et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr. Relat. Cancer 13(2), 541-558 (2006).
84. Missiaglia E, Dalai I, Barbi S et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J. Clin. Oncol. 28(2), 245-255 (2010).